NCT02268435

Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors

A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Asan Medical Center · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to determine the recommended dose of combination of dovitinib and imatinib in phase I study.

Detailed description

combination of dovitinib and imatinib could lead to additive or synergistic effect in patients who had failure of standard TKI therapies including imatinib, sunitinib, and/or regorafenib. In this phase I-II study of dovitinib plus imatinib, we aim to determine a recommended dose of dovitinib plus imatinib and to evaluate the safety and activity of the combination at the recommended dose as a 3rd or more line of treatment in metastatic or unresectable GIST.

Conditions

• Gastrointestinal Stromal Tumors

Interventions

Type	Name	Description
DRUG	dovitinib plus imatinib	Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule

Timeline

• Start date: 2015-03-01
• Primary completion: 2016-08-01
• Completion: 2016-11-01
• First posted: 2014-10-20
• Last updated: 2015-08-04